ALEX CAPUCHINO: Open Payments
NPI 1386395762 · SAN BERNARDINO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,821 in 205 payments from 13 companies in 2025. Trend: 2023 $123 · 2024 $2,464 · 2025 $4,821
Food & beverage: $4,821
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 66 | $1,641 |
| Otsuka America Pharmaceutical, Inc. | 30 | $867 |
| Teva Pharmaceuticals USA, Inc. | 25 | $535 |
| Vanda Pharmaceuticals Inc. | 15 | $377 |
| Neurocrine BioSciences, Inc. | 14 | $333 |
| Janssen Pharmaceuticals, Inc | 11 | $318 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $199 |
| Noven Therapeutics, LLC | 13 | $141 |
| Axsome Therapeutics, Inc. | 6 | $130 |
| Alkermes, Inc. | 5 | $99 |
Products named: VRAYLAR, REXULTI, INGREZZA, UZEDY, AUSTEDO XR, HETLIOZ, CAPLYTA, FANAPT.
Industry payments across CA — which companies pay providers there.
